Japan Approves VTAMA Cream for Pediatric Atopic Dermatitis
Shionogi & Co., Ltd. and Torii Pharmaceutical Co., Ltd. have secured manufacturing and marketing approval in Japan for VTAMA® Cream 0.5% (tapinarof) to treat atopic dermatitis in children under 12. This nonsteroidal, aryl hydrocarbon receptor modulating agent offers a new therapeutic option for pediatric patients suffering from the skin condition. The approval expands treatment choices for a common childhood ailment.
Want more?
Open NewsSnap.ai for the full app experience, including audio, personalization, and more news tools.
Open NewsSnap.ai